Clinical trials: Early Onset Parkinson Disease, active
Parkinson's Disease (PD), Early Onset Parkinson Disease
AAV2-hAADC for Parkinson's Disease (PDCS-01)
This study is looking at whether a gene therapy called AAV2-hAADC is safe and may help people with Parkinson's Disease. AAV2-hAADC is intended to increase the levels of dopamine in your brain.
- Trial name
- PDCS-01 (NCT07267065)
- Testing
- AAV2-hAADC
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Russell Lonser
Parkinson Disease
Chinese EOPD Registry
The purpose of the Chinese Early-onst Parkinson's disease Registry (CEOPDR) is to develop a database of persons with early-onset Parkinson's disease (EOPD) in China.
- Trial name
- NCT03508960
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Xiangya Hospital of Central South University
Parkinson's Disease (PD)
Empower Your Mind to Embrace Your Life: an Online ACT Intervention for Young-Onset Parkinson's Disease
Parkinson's disease (PD) has a substantial impact on daily life and significantly affects functioning, mental health and quality of life. Although considered a disease of the elderly, an early diagnosis is also common.
- Trial name
- NCT07310147
- Testing
- Empower your mind to embrace your life
- Where
- Portugal
- Volunteers
- 20 people
- Sponsor
- University of Coimbra
ALS, Amyotrophic Lateral Sclerosis
NYSCF Scientific Discovery Biobank
The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells…
- Conditions
- ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset
- Trial name
- NCT06203106
- Testing
- Biological Sample Collection
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- New York Stem Cell Foundation Research Institute
Alzheimer Disease, Early Onset, Parkinson Disease
Network-based biOmarker Discovery of Neurodegenerative Diseases Using Multimodal Connectivity
The aim of the NODAL clinical trial is to demonstrate the feasibility of new, low-cost, non-invasive biomarkers of neurodegenerative pathologies as early Alzheimer and Parkinson, based on the estimation of the multimodal…
- Trial name
- NODAL (NCT06080659)
- Testing
- fMRI, CONFMEM
- Where
- France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Rennes University Hospital
Parkinson's Disease, Parkinsonism
Parkinson's Families Project
One person in every 500 has Parkinson's and around 127,000 people are living with the condition in the UK. The aim of the study is to identify new genes that predispose or cause Parkinson's Disease or Parkinsonism.
- Trial name
- PFP (NCT02760108)
- Where
- 2 sites in United Kingdom
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- University College, London
Alzheimer Disease, Early Onset, Parkinsons Disease with Dementia
Neuropsychological Profiles and Musical Engagement in Parkinson's and Alzheimer's Disease
The goal of this Multicenter observational pilot study is to Compare the specifics of musical engagement (behaviors related to music in everyday life) in subjects aged over 60 with Alzheimer s disease, Parkinson s disease and…
- Conditions
- Alzheimer Disease, Early Onset, Parkinsons Disease with Dementia, Non Pharmacological Intervention
- Trial name
- MUSENGAGE (NCT06688968)
- Testing
- neuropsychologist interview, questionnaire
- Where
- 3 sites in France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Parkinson's Disease (PD), Parkinson Disease 6, Early-Onset
Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of TJ0113 Capsules in Patients With Early-Onset Parkinson's Disease
This study is a randomized, double-blind, multicenter, placebo-controlled Phase III clinical trial designed to evaluate the efficacy, safety, and Pop PK characteristics of TJ0113 Capsules in treating EOPD patients.
- Trial name
- NCT07741045
- Testing
- TJ0113 200mg, TJ0113 400mg
- Where
- 21 sites in China
- Volunteers
- 300 people
- Sponsor
- Hangzhou PhecdaMed Co., Ltd.
Parkinson Disease, Parkinson Disease 6, Early-Onset
A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease
The purpose of this study is to evaluate the safety, tolerability, immunogenicity, and pharmacodynamic effects of ACI-7104.056 in patients with early stages of Parkinson's disease.
- Trial name
- VacSYn (NCT06015841)
- Testing
- ACI-7104.056 at Dose A, ACI-7104.056 at Dose B (optional), ACI-7104.056 at Dose C (optional)
- Where
- 12 sites in Germany, Spain and 1 more
- Volunteers
- 150 people
- Sponsor
- AC Immune SA
Young Onset Parkinson Disease, Parkinson Disease
Young Onset Parkinson's Disease Subtypes and Pathogenic Mechanisms
Young Onset Parkinson's disease (YOPD) refers to a group of patients in which the disease starts earlier in life (before the age of 50 years) and has a profound impact on most of patient's life.
- Trial name
- YOPD (NCT07752355)
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Early-onset Parkinson's Disease
The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset Parkinson's Disease
The goal of this clinical trial is to learn about the safety of NouvNeu001 injection in Early-onset Parkinson's Disease (EOPD) patients. It will also learn about the effects of NouvNeu001 treatment.
- Trial name
- NCT06608355
- Testing
- Human Dopaminergic Progenitor Cells
- Where
- China
- Volunteers
- 6 people
- Sponsor
- iRegene Therapeutics Co., Ltd.
Parkinson Disease (PD)
Clinical Study to Evaluate XS411 in Treatment of Early-onset Parkinson's Disease
This study is a Phase I/II clinical study to evaluate the safety, tolerability, and efficacy of XS411 in the treatment of EOPD. The study consists of two phases: Phase I and Phase II.
- Trial name
- NCT07166757
- Testing
- human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection
- Where
- China
- Volunteers
- 90 people
- Sponsor
- XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.